Immunotherapy: Changing Patient Outcomes in SCLC

Program Overview

Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with a poor prognosis. The recent addition of immunotherapy to the treatment landscape has changed the standard of care for ES-SCLC. In this interactive activity an expert will guide you through the latest evidence on checkpoint inhibitors for the management of ES-SCLC and offer expert insight into effectively and safely incorporating immunotherapy into your practice to improve patient outcomes.

Credit Expired

CE Credit Expired

Target Audience

The intended audience for this activity is oncologists, as well as PAs and NPs, who manage patients with small cell lung cancer (SCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Describe the mechanism of action of immune checkpoint inhibitors in small cell lung cancer (SCLC) and how this impacts their efficacy in managing SCLC
Utilize an evidence-based approach to managing SCLC with current and emerging immunotherapies
Proactively manage potential side effects of immunotherapies
Employ a strong patient-provider collaborative approach, including shared decision making, to actively educate and engage patients with SCLC in their care

Activity Faculty

Leora Horn, MD, MSc

Associate Professor, Medicine
Assistant Director, Educator Development Program
Clinical Director, Thoracic Oncology Program
Vanderbilt University Medical Center
Nashville, TN